Catherine Wood, CEO and CIO at ARK Investment Management (ARK), invests on the cutting edge of robotics, energy storage, next-generation internet and blockchain technology. However it is in the field of genomic sequencing that she tell us: “Something is happening that is more profound than I’ve ever experienced”.
- A revolutionary gene-editing technology has emerged that may potentially hold the cure for some diseases. The first human trials in the US are taking place this year in cases of paediatric blindness.
- Another technology that ARK is backing can turn a patient’s immune system against cancerous cells. It is yielding promising results in non-Hodgkin’s lymphoma.
ARK Investment Management is a Nikko Asset Management strategic partner. This material is issued in Australia by Nikko AM Limited ABN 99 003 376 252, AFSL 237563.